1. Early Marketplace Enrollees Were Older And Used More Medication Than Later Enrollees; Marketplaces Pooled Risk.

    Health Affairs 34(6):1049 (2015) PMID 26019223

    Little is known about the health status of the 7.3 million Americans who enrolled in insurance plans through the Marketplaces established by the Affordable Care Act in 2014. Medication use may provide an early indicator of the health needs and access to care among Marketplace enrollees. We used ...
  2. Medicare's Step Back from Global Payments - Unbundling Postoperative Care.

    New England Journal of Medicine 372(15):1385 (2015) PMID 25839843

    Owing to concerns about the accuracy of payments for postoperative care, the Centers for Medicare and Medicaid Services has announced that surgeries for which it has bundled payments for care during a 10- or 90-day global period will be shifted to a 0-day global period.
  3. Medicare's Step Back from Global Payments - Unbundling Postoperative Care.

    New England Journal of Medicine 372(15):1385 (2015) PMID 25839843

    Owing to concerns about the accuracy of payments for postoperative care, the Centers for Medicare and Medicaid Services has announced that surgeries for which it has bundled payments for care during a 10- or 90-day global period will be shifted to a 0-day global period.
  4. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

    Health Economics 24(2):238 (2015) PMID 24293058 PMCID PMC4320771

    This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and low-income countries (MLICs), with robustness checks to other therapeutic categories and the full income range of count...
  5. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

    Health Economics 24(2):238 (2015) PMID 24293058 PMCID PMC4320771

    This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and low-income countries (MLICs), with robustness checks to other therapeutic categories and the full income range of count...
  6. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

    Health Economics 24(2):238 (2015) PMID 24293058 PMCID PMC4320771

    This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and low-income countries (MLICs), with robustness checks to other therapeutic categories and the full income range of count...
  7. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

    Health Economics 24(2):238 (2015) PMID 24293058 PMCID PMC4320771

    This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and low-income countries (MLICs), with robustness checks to other therapeutic categories and the full income range of count...
  8. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

    Health Economics 24(2):238 (2015) PMID 24293058

    This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and low-income countries (MLICs), with robustness checks to other therapeutic categories and the full income range of count...
  9. Closing the quality gap: revisiting the state of the science (vol. 1: bundled payment: effects on health care spending and quality).

    Evidence report/technology assessment (208.1):1 (2012) PMID 24422914

    "Bundled payment" is a method in which payments to health care providers are related to the predetermined expected costs of a grouping, or "bundle," of related health care services. The intent of bundled payment systems is to decrease health care spending while improving or maintaining the quali...
  10. Closing the quality gap: revisiting the state of the science (vol. 1: bundled payment: effects on health care spending and quality).

    Evidence report/technology assessment (208.1):1 (2012) PMID 24422914

    "Bundled payment" is a method in which payments to health care providers are related to the predetermined expected costs of a grouping, or "bundle," of related health care services. The intent of bundled payment systems is to decrease health care spending while improving or maintaining the quali...
  11. Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries.

    Health Affairs 30(8):1529 (2011) PMID 21821570

    Finding better mechanisms to enable differential pricing that reflects different degrees of willingness to pay across countries with different income levels is an important challenge for drug manufacturers and policy makers. Drug prices must be high enough to meet manufacturers' needs--covering ...
  12. Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries.

    Health Affairs 30(8):1529 (2011) PMID 21821570

    Finding better mechanisms to enable differential pricing that reflects different degrees of willingness to pay across countries with different income levels is an important challenge for drug manufacturers and policy makers. Drug prices must be high enough to meet manufacturers' needs--covering ...